Abbott Launches Panbio™ COVID-19 Antigen Self-Test in India; Strengthens Rapid Diagnostics Portfolio to Support Testing Needs at Home, Work and at Clinics

  • Panbio™ COVID-19 Antigen Self-Test has received CE Mark for over-the-counter use in adults and children, with or without symptoms
  • The self-test features a minimally invasive nasal swab and delivers results in as early as 15 minutes with no instrumentation, using proven Abbott lateral flow technology
  • Automatic reading of test results and fast, easy online reporting to Indian Council of Medical Research (ICMR) via Abbott’s NAVICA™ reporting app
  • In clinical evaluations with self-test users, the Panbio Self-Test correctly identified 95.2% of positive samples and 100% of negative samples

MUMBAI, July 12, 2021 —Abbott has announced the launch of Panbio™ COVID-19 Antigen Self-Test for the detection of the SARS-CoV-2 virus in adults and children with or without symptoms. In alignment with the current ICMR advisory on self-use, these tests will be made available to ramp up testing of symptomatic and asymptomatic individuals and contacts of confirmed coronavirus cases.

Abbott will deliver millions of Panbio COVID-19 Rapid Antigen Tests available for self-use to ease the burden on healthcare systems in urban and rural India. Since the tests provide critical information at a point in the infection cycle when people are at the highest risk of spreading the disease, they can be a powerful tool to slow the spread of infection.

"India needs a clear, multi-pronged COVID-19 response strategy," said Professor Nirmal Kumar Ganguly, former Director General, ICMR. "Scaling access to easy, accurate and fast testing can speed up the country’s preparedness and curb community contagion. Self-testing at home empowers individuals with the ability to carry out the first line of protection against disease transmission. This not only streamlines the process of isolation, tracing and tracking but also supports people in taking charge of their own health and enhances participation of individuals willingly."

In India, Abbott will offer self-tests for use at home, assisted professional testing at point of care and laboratories, as well as workplace testing to help enable a sense of normalcy in returning to places of employment.

"Rapid antigen testing is critical in the fight against COVID-19 and Abbott is delivering a variety of diagnostics options at a critical juncture in the pandemic," said Sanjeev Johar, divisional vice president of Abbott’s rapid diagnostics business in Asia Pacific. "Self-testing is a proven tool that provides an added layer of defense along with public health protocols and the vaccine roll out."

Self-Tests enable fast testing and reporting to help curb the spread of infection 

The Panbio COVID-19 Antigen Self-Test is easy-to-use, and people can take the test by using a simple nasal swab (not the deep nasopharyngeal swab) while following the Instructions for Use steps on pack. For children younger than 14 years, an adult caretaker should help collect the nasal samples and conduct the test procedures.  The kit contains all the materials required including nasal swabs, test devices and reagent ampules. No additional instrumentation is required to conduct the test. 

Self-test kits are offered in packages of one, four, 10 and 20 tests. With results in just 15 minutes, the Panbio COVID-19 Antigen Self-Test enables people who test positive to immediately isolate so that they do not infect others, rather than waiting days for results.

The test is to be used along with Abbott’s NAVICA mobile app, available in the Google Play and Apple app store. The app offers a simple and streamlined process of self-registration, automatic reading of results and easy reporting as per ICMR guidelines. Panbio Self-Tests will be available via retail pharmacies and through e-commerce platforms, as well as through organizations and institutions.

Rapid point of care testing delivers timely health information to inform treatment

Abbott has multiple professional use diagnostic test options in India that deliver reliable, on-the-spot results. Abbott offers the Panbio™ COVID-19 Ag Rapid Test Device for professional use. This version of the test – which is scientifically identical to the self-test– can be administered by health professionals on adults and children, with or without symptoms. Like the Panbio Self-Test, the professional test offers a minimally invasive nasal swab option for the assisted, supervised sample collection, which can help people who are not comfortable with the deep nasopharyngeal swab. It delivers results in 15 minutes. 

The Panbio professional test demonstrated 95.7% sensitivity and 97.6% specificity when benchmarked against RT-PCR tests, indicating high reliability.i Abbott is the only diagnostics manufacturer to provide performance data on a rapid antigen test specific for use on children who are 15 years and younger, including infants. Panbio has CE Mark for asymptomatic use and supervised nasal swab collection and is on the World Health Organization (WHO) Emergency Use Listing.

Since last August to date, Abbott has shipped 300 million Panbio COVID-19 Antigen Rapid tests for professional use in more than 100 countries across Europe, the Americas, Asia and Africa.

Also available is Abbott’s ID NOW system, a molecular point-of-care test the size of a toaster that's designed to deliver results in less than 15 minutes. ID NOW is being widely being used at airports, emergency departments, diagnostics laboratories and in a wide variety of other point-of-care settings.

For more information on Abbott’s Rapid Diagnostics portfolio in India visit: https://www.globalpointofcare.abbott/en/index.html.

About Abbott

Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 109,000 colleagues serve people in more than 160 countries.

Connect with us at www.abbott.com, on LinkedIn at www.linkedin.com/company/abbott-/, on Facebook at www.facebook.com/Abbott and on Twitter @AbbottNews. 


Abbott Media:

Nandini Goswami, 8291296377
Krishna Vilasini Bharadwaj, 8433926550  


References:

i Report on evaluation of Panbio COVID-19 Ag Rapid Test Device (NASAL), SARS CoV-2 antigen test kits, Jawaharlal Institute of Postgraduate Medical Education & Research (JIPMER), April 2021

true
accessibility

You are about to exit for another Abbott country or region specific website

Please be aware that the website you have requested is intended for the residents of a particular country or region, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.


The website you have requested also may not be optimized for your specific screen size.

Do you wish to continue and exit this website?

accessibility

You are about to exit the Abbott family of websites for a 3rd party website

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.


The website that you have requested also may not be optimized for your screen size.

Do you wish to continue and exit this website?